background
human
coronaviru
recent
identifi
coronaviru
global
distribut
known
caus
mainli
respiratori
infect
object
investig
seroepidemiolog
infect
local
popul
studi
design
elisabas
igg
antibodi
detect
assay
use
recombin
nucleocapsid
spike
protein
genotyp
develop
diagnosi
infect
addit
neutral
antibodi
assay
use
pseudotyp
viru
develop
detect
presenc
neutral
antibodi
serum
antibodi
posit
proteinbas
elisa
result
result
recombin
proteinbas
elisa
valid
western
blot
immunofluoresc
analysi
flow
cytometri
coupl
result
demonstr
good
correl
spearmen
coeffici
seroepidemiolog
studi
local
hospitalbas
set
use
newli
develop
elisa
show
steadili
increas
seropreval
childhood
earli
adulthood
age
group
year
old
plateau
age
group
year
old
conclus
studi
demonstr
use
sbase
elisa
could
appli
futur
epidemiolog
studi
local
coronaviru
newli
identifi
human
coronaviru
global
distribut
first
report
hong
kong
usa
australia
europ
report
incid
vari
patient
hospit
acut
pulmonari
extrapulmonari
symptom
laboratori
detect
mostli
achiev
rtpcr
nucleocapsid
protein
highli
conserv
success
clone
use
detect
antibodi
respons
enzym
immunoassay
eia
western
blot
analysi
sera
infect
human
ideal
antibodi
test
viral
infect
presenc
neutral
antibodi
neutral
antibodi
shown
long
last
protect
immun
respons
mani
viral
infect
includ
coronaviru
util
assay
base
neutral
antibodi
respons
pseudotyp
human
coronavirus
success
report
success
propag
cultur
possibl
determin
measur
neutral
antibodi
respons
viru
first
report
examin
seroepidemiolog
make
use
pseudotyp
viru
confirm
presenc
neutral
antibodi
serolog
posit
serum
evalu
preval
caus
respiratori
tract
infect
variou
age
group
local
popul
analyz
serum
sampl
assay
concurr
recombin
protein
nucleocapsid
spike
base
elisa
establish
baselin
valu
confirm
western
blot
immunofluoresc
microscopi
flow
cytometri
presenc
neutral
antibodi
pseudotyp
viru
screen
anoth
serum
sampl
variou
age
group
found
studi
popul
age
associ
infect
implic
recent
identifi
viru
alreadi
endem
commun
recombin
tag
n
protein
express
report
briefli
express
n
protein
bound
nickel
hitrap
column
amersham
bioscienc
purifi
protein
elut
use
akta
explor
system
amersham
bioscienc
human
codon
optim
cdna
code
genotyp
synthes
serv
templat
spike
fragment
amplif
cover
amino
acid
residu
clone
bacteri
express
vector
amersham
bioscienc
ntermin
fuse
glutathion
stransferas
gst
gene
recombin
protein
express
escherichia
coli
cell
clone
primer
sequenc
list
tabl
index
serum
control
obtain
previous
report
case
infect
neg
control
obtain
leftov
sera
infant
month
age
control
sera
use
calibr
elisa
assay
total
random
sampl
patient
hospit
acut
respiratori
ill
use
evalu
elisabas
igg
antibodi
detect
assay
design
standard
previous
report
briefli
recombin
n
antigen
gml
respect
coat
onto
immunopl
maxisorb
nunc
l
test
serum
dilut
test
duplic
purifi
gsttag
spike
nucleocapsid
n
load
sdspolyacrylamid
gel
separ
transfer
polyvinyliden
difluorid
pvdf
membran
amersham
bioscienc
result
reveal
use
ecl
system
amersham
bioscienc
full
length
human
codon
optim
spike
gene
atrich
codon
wildtyp
sequenc
replac
synonym
gcrich
codon
correspond
frequent
use
human
codon
clone
pcdna
cotransfect
lentivir
vector
contain
report
gene
gfp
use
pseudotyp
viru
product
neutral
assay
base
pseudotyp
viru
perform
measur
infect
cell
carcinom
human
alveolar
basal
epitheli
cell
indic
express
green
fluoresc
protein
gfp
preheat
inactiv
serum
sampl
twofold
serial
dilut
mix
ng
pseudotyp
viru
pseudotyp
viru
quantit
use
elisa
kit
viru
infect
determin
h
postinfect
measur
mean
fluoresc
level
express
infect
cell
flow
cytometri
beckton
dickinson
facscalibur
neutral
antibodi
titer
determin
percentag
inhibit
viru
infect
mean
fluoresc
final
dilut
patient
serum
inhibit
pseudotyp
viru
infect
id
compar
viral
infect
without
treatment
serum
human
codon
optim
cdna
code
subclon
ctermin
fuse
infram
flag
sequenc
dykddddk
bam
hi
site
semliki
forest
viral
express
vector
result
plasmid
tabl
comparison
result
elisa
use
spike
nucleocapsid
confirm
western
blot
true
posit
sampl
protein
spike
test
presenc
antibodi
viru
spike
envelop
compar
imag
analysi
fluoresc
microscopi
eclips
nikon
establish
baselin
elisa
test
cutoff
determin
mean
optic
densiti
valu
plu
three
standard
deviat
nm
observ
result
mean
elisa
od
nbase
test
standard
deviat
respect
absorb
valu
select
cutoff
valu
nbase
elisa
test
respec
sbasedelisa
neg
sampl
serum
c
taken
patient
recov
infect
sera
dn
sampl
basedelisa
posit
od
od
tive
fig
refer
standard
found
sampl
posit
n
posit
n
neg
sbase
elisa
tabl
sampl
found
posit
neg
n
antigen
confirmatori
western
blot
done
elisa
seroposit
sampl
sampl
test
posit
nbase
elisa
also
posit
western
blot
respect
antigen
tabl
fig
posit
nbase
elisa
sampl
found
produc
weakli
posit
protein
band
n
kda
none
kda
western
blot
seroneg
sampl
remain
neg
western
blot
discrep
result
elisa
system
western
blot
assay
achiev
assay
detect
neutral
antibodi
nab
uncultur
shown
infect
could
block
convalesc
patient
serum
recov
infect
inhibit
appear
specif
serum
neutral
vsvg
envelop
pseudotyp
retrovir
particl
fig
serum
patient
recov
coronaviru
infect
sar
nonsar
human
coronaviru
block
viru
infect
fig
crossreact
antigen
shown
western
blot
fig
demonstr
viru
serv
surrog
tool
detect
neutral
antibodi
assess
correl
presenc
neutral
antibodi
elisa
baselin
analyz
sbase
elisa
posit
sera
two
randomli
select
neg
sampl
along
index
patient
serum
posit
control
neutral
assay
neutral
antibodi
detect
serum
sampl
sbase
elisa
absorb
valu
score
gave
result
correspond
neutral
antibodi
titer
id
detect
neutral
activ
correspond
titer
found
sampl
score
detect
antibodi
nativ
protein
express
cell
indirect
immunofluoresc
microscopi
sera
b
sbase
elisa
neg
sampl
serum
c
taken
patient
recov
infect
sera
dn
sampl
sbase
elisa
posit
od
od
two
differ
bind
assay
appli
detect
sspecif
antibodi
seroposit
sampl
use
flow
cytometri
immunofluoresc
microscop
analysi
sexpress
cell
fig
order
correl
result
elisa
neutral
assay
tabl
distinct
antibodi
signal
flow
cytometri
detect
sampl
score
absorb
valu
fig
sera
net
geometr
mean
fluoresc
intens
mfi
although
weaker
signal
observ
sampl
lower
absorb
valu
net
mfi
fig
sampl
good
posit
correl
neutral
assay
shown
elisa
flow
cytometri
suggest
proteintarget
serolog
assay
reliabl
indic
predict
presenc
neutral
antibodi
sbase
seroposit
sampl
elisa
absorb
score
blood
sampl
collect
patient
attend
queen
mari
hospit
found
clinic
free
activ
respiratori
infect
categor
differ
age
group
analyz
igg
level
spike
protein
elisa
method
describ
fig
refer
cutoff
standard
determin
previou
test
mean
absorb
percentag
popul
predict
neutral
antibodi
protein
group
shown
fig
anova
analysi
show
signific
differ
sampl
mean
among
age
group
newli
identifi
human
coronaviru
consist
detect
respiratori
specimen
patient
suffer
respiratori
tract
infect
multitud
studi
around
world
preval
found
gener
compar
nonsar
human
coronavirus
local
popul
particularli
winter
season
individu
may
probabl
experi
coronaviru
infect
carri
antibodi
first
report
examin
seroepidemiolog
seropreval
includ
neutral
test
one
determin
paramet
first
public
elisa
base
antibodi
test
made
nucleocapsid
n
protein
seroconvers
observ
index
patient
high
percentag
sequenc
conserv
result
falseposit
render
ideal
singl
marker
serodiagnosi
despit
antigen
regard
minim
crossreact
incorpor
spike
protein
addit
marker
exhibit
least
exhibit
sequenc
conserv
among
coronaviru
protein
result
wb
analysi
support
specif
n
sbase
elisa
seroposit
serum
cutoff
valu
fail
wb
test
target
antigen
expect
nbase
seroposit
sampl
test
neg
sbase
assay
indic
inclus
doubl
marker
critic
curtail
falseposit
rate
nonspecif
neutral
result
gener
consist
sampl
obtain
elisa
score
cutoff
neutralizationneg
sbase
posit
sampl
detect
contain
low
level
sproteinspecif
antibodi
bind
assay
immunofluoresc
microscopi
flow
cytometri
use
sexpress
cell
fig
tabl
consist
result
bind
assay
pseudoviru
neutral
test
achiev
elisa
cutoff
rais
sampl
justifi
set
cutoff
high
level
insur
reliabl
index
determin
seropreval
exclud
falseposit
pose
presenc
human
coronaviru
antibodi
base
standard
determin
result
show
rise
trend
seropreval
age
group
peak
group
declin
age
group
seroposit
case
identifi
age
group
fig
pattern
within
expect
incid
infect
found
rel
low
hong
kong
report
mostli
target
patient
respiratori
symptom
use
rtpcr
viral
detect
would
identifi
case
activ
diseas
contrast
studi
exclud
sera
patient
respiratori
symptom
detect
specif
igg
antibodi
would
allow
better
estim
incid
wider
popul
studi
truli
populationbas
especi
includ
extrarespiratori
diseas
present
result
still
demonstr
substanti
adult
popul
demonstr
immun
one
limit
newli
develop
assay
util
protein
genotyp
current
three
known
genotyp
b
c
circul
protein
genotyp
b
share
amino
acid
similar
protein
genotyp
c
aris
recombin
genotyp
b
ident
genotyp
b
like
appreci
degre
crossreact
two
close
relat
protein
henc
test
may
pick
patient
infect
genotyp
b
incorpor
protein
genotyp
b
import
area
improv
futur
develop
assay
develop
vaccin
possibl
best
strategi
protect
infect
predominantli
nonimmun
popul
reduc
risk
major
outbreak
recent
success
produc
infecti
full
length
cdna
clone
would
pave
way
develop
genet
engin
live
attenu
protect
vaccin
assay
develop
present
work
would
valuabl
studi
humor
immun
respons
guid
drug
vaccin
design
